Synairgen share price: Is it too late for investors to profit after the 400% price rise?

If you missed out on the 400% rise in the Synairgen stock price, then there still might be a chance to get on board for further gains.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Synairgen share price shot up by over 400% on 20 July after positive results from a trial of a potential Covid-19 treatment. The current price – of around 220p – is the highest that shares in the drug discovery and development company have traded at since 2005.

Potential investors will no doubt be asking if they have missed the chance to profit from Synairgen stock. To answer that question, let us first consider what the treatment was and what the successful trial results mean.

Trialling times

Interferon-beta (IFN-beta) coordinates immune responses. There is evidence that decreased production of INF-beta in the lungs makes people more susceptible to severe lung disease with viral infections. There is also evidence that viruses, including the coronavirus, have mechanisms to suppress INF-beta production.

Synairgen developed an inhaled formulation of INF-beta, called SNG001. SNG001 is already proven to be well tolerated in asthma and COPD patients. The results reported by Synairgen on 20 July concern 100 patients hospitalised with Covid-19. In addition to other therapy, they were randomised to receive either a placebo or SNG001. Patients treated with SNG001 were less likely to develop severe disease, and twice as likely to recover. 

Synairgen share price rise

The methodology of the trial was sound but the sample size was small. Nevertheless, the results were encouraging and made it more likely that SNG001 will be approved for use in the treatment of lung disease with Covid-19 infections. This is why the Synairgen share price rose by over 400%. If formal approval is granted it could boost the share price further. Also, results are awaited from another part of the same trial: 120 Covid-19 patients treated in the community with SNG001 are still under investigation.

It is the community patient part of the trial that I find more compelling. It aims to discover if SNG001 prevents Covid-19 patients from deteriorating to the point that they need hospital care. A positive result here would substantially expand the size of the market for SGN001 – since relatively few Covid-19 patients end up in the hospital – and could drive the share price higher.

Taking stock

But investors do need to bear something in mind with SNG001. AstraZeneca licensed it for use in all respiratory indications in 2014. Synairgen received $7.25m up-front with $225m worth of potential milestone payments plus tiered royalties up to the mid-teens depending on future sales. AstraZeneca was looking at SNG001 in the main as a treatment for asthma and COPD. These are chronic respiratory conditions that affect around 1 in 13 and 1 in 15.7 people, respectively. 

The highest the Synairgen share price got on the back of the AstraZeneca deal was 86p. Eventually, AstraZeneca returned all rights to SNG001 back to Synairgen, after disappointing progress in trials for the treatment of asthma. The Synairgen stock price eventually retreated to under 10p.

Synairgen is likely looking for another licence agreement for SNG001, predicated on its use as a treatment for Covid-19. Will they get a better deal than the original AstraZeneca one? What I am getting at is that the reaction to last week’s news might have been over the top. But, if the reaction to future positive news is as exuberant, then the Synairgen share price could move even higher.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James J. McCombie has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »